Released Aug 9, 2024, after the close
10-Q filed Aug 9, 2024, 40 days after period end · 0000950170-24-094727
Q2 2024 · 10-Q
Revenue—
Net Income-$8.39M-$8.39M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$246.27-$246.27 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$2,522,397N/M
Operating Cash Flowderived-$2,478,682N/M
Free Cash Flowderived-$2,478,682N/M
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$8.39M | -$1.45M | -$1.83M | -$2.47M |
| EPS Diluted | -$246.27 | -$5.83 | -$4.16 | -$0.39 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR